Unicycive Therapeutics Inc (UNCY) Share Price Today, Stock Analysis, Annual Report | Value Research Unicycive Therapeutics Inc (UNCY) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.

Unicycive Therapeutics Inc (UNCY)

Download Stock Report

NASDAQ: UNCY

  • Price Change
  • Market Capitalisation market-capitalisation-info $21 Mln

  • 12 Month Earnings monthly-earning $-9 Mln
  • Price to Earnings price-to-earning --

Unicycive Therapeutics Inc (UNCY) Share Price

$0.92

As on 02-Oct-2023 16:00 EDT

up-down-arrow $0.066.97%

  • Prev Close info

    $0.86

  • Day's Openinfo

    $0.91

  • Today's Highinfo

    $0.94

  • Today's Lowinfo

    $0.90

  • Today's Volumeinfo

    42,371

Please wait...

Unicycive Therapeutics Inc (UNCY) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Unicycive Therapeutics Inc (UNCY)
70.35 14.99 -28.13 55.92 -- -- --
S&P BSE Sensex*
7.86 0.36 1.40 14.28 19.25 12.43 12.89
#
-- -- -- -- -- -- --
As on 02-Oct-2023  |  *As on 03-Oct-2023  |  #As on
2022
Unicycive Therapeutics Inc (UNCY)
-73.79
S&P BSE Sensex
4.44
S&P BSE Sensex
4.44

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Unicycive Therapeutics Inc (UNCY) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Unicycive Therapeutics Inc (UNCY)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Founder, Chairman, CEO & Pres

        Dr. Shalabh K. Gupta M.D., MPA

        Chief Financial Officer

        Mr. John W. Townsend CPA

        Headquarters

        Los Altos, CA

        FAQs for Unicycive Therapeutics Inc (UNCY)

        The total asset value of Unicycive Therapeutics Inc (UNCY) stood at $ 43 Mln as on 31-Mar-23

        The share price of Unicycive Therapeutics Inc (UNCY) is $0.92 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Unicycive Therapeutics Inc (UNCY) has given a return of 55.92% in the last 1 years.

        Unicycive Therapeutics Inc (UNCY) has a market capitalisation of $ 21 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Unicycive Therapeutics Inc (UNCY) is 2.44 times as on 02-Jun-2023, a -0.04% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Unicycive Therapeutics Inc (UNCY) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Unicycive Therapeutics Inc (UNCY) and enter the required number of quantities and click on buy to purchase the shares of Unicycive Therapeutics Inc (UNCY).

        Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

        The CEO & director of Dr. Shalabh K. Gupta M.D., MPA. is Unicycive Therapeutics Inc (UNCY), and CFO & Sr. VP is Mr. John W. Townsend CPA.

        The promoters of Unicycive Therapeutics Inc (UNCY) have pledged 0% of the total equity as on Dec-22.

        Unicycive Therapeutics Inc (UNCY) Ratios
        Return on equity(%)
        -524.06
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Unicycive Therapeutics Inc (UNCY) was $-9 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $21.17 Mln
        • Revenue (TTM)revenue-information $1.63 Mln
        • Earnings (TTM) earning-information $-9.19 Mln
        • Cash date-information $24.33 Mln
        • Total Debt info $0.99 Mln
        • Insider's Holding 41.27%
        • Liquidity liquidity High
        • 52 Week range week-range $0.40 - 2.87
        • Shares outstanding share-outstanding 15,233,800
        • 5 Years Aggregate:

          CFO: $-24.83 Mln

          EBITDA: $-31.01 Mln

          Net Profit: $-33.61 Mln

        About The Company

        • IPO Date 12-Jul-2021
        • Founder, Chairman, CEO & Pres Dr. Shalabh K. Gupta M.D., MPA
        • Chief Financial Officer Mr. John W. Townsend CPA
        • Listing key-listing NASDAQ: UNCY
        • Country United States
        • Headquarters headquarters Los Altos, CA
        • Website website https://www.unicycive.com
        • Business

          Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis;...  and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon